New York, May 21, 2026, 14:05 EDT
- Puma Biotechnology shares edged up in early afternoon trading, lagging a firmer biotech tape.
- The company’s latest investor update remains its May 7 first-quarter report, when it raised 2026 revenue and net income guidance.
- The stock story is still tied closely to NERLYNX demand and the cost of advancing alisertib trials.
Puma Biotechnology shares edged higher on Thursday, with the cancer-drug maker trading at $7.01, up 0.3%, after moving between $6.85 and $7.08 during the session. The stock lagged the SPDR S&P Biotech ETF, a broad biotech fund, which rose about 1.1%.
The move was modest, but it matters now because there was no fresh company-specific release to reprice the shares. Puma’s investor page still listed its May 7 first-quarter results and a May 6 inducement-award notice as its most recent news items.
That leaves investors trading off the same core issue: whether Puma can turn stronger demand for NERLYNX, its breast-cancer drug, into steadier profit while it spends more on clinical development.
Puma, listed on the Nasdaq Global Select Market under PBYI, filed an 8-K on May 7 for its quarterly results. An 8-K is a U.S. filing companies use to report material events.
The company reported first-quarter total revenue of $44.8 million, down from $46.0 million a year earlier. Product revenue from NERLYNX was $42.0 million, against $43.1 million in the prior-year quarter.
On U.S. accounting rules, known as GAAP, Puma posted a net loss of $3.8 million, or 7 cents a share, compared with net income of $3.0 million a year earlier. On a non-GAAP basis, an adjusted measure that excludes stock-based compensation, the loss was $1.9 million, or 4 cents a share.
The stronger part of the update was guidance. Puma raised its 2026 total revenue forecast to $222 million to $229 million from $214 million to $221 million, and lifted its net income view to $16 million to $19 million from $10 million to $13 million.
Alan H. Auerbach, Puma’s chairman, chief executive and president, said the quarter showed “year-over-year demand increase” for NERLYNX. He also said Puma was “carefully managing our resources” as it targets positive net income this year. Puma Biotechnology, Inc.
The balance sheet also changed. Puma said it made the final payment due under its 2021 note purchase agreement on May 4, cutting outstanding debt to zero except for customary continuing indemnification obligations.
Competitive pressure remains part of the picture. In HER2-positive breast cancer — HER2 is a protein that can drive some breast cancers — Puma’s NERLYNX sits in a crowded treatment field that includes Genentech’s Herceptin and Perjeta, Daiichi Sankyo’s Enhertu and Seagen’s Tukysa, according to Puma’s annual filing.
But the downside case is plain enough. Puma said in its quarterly filing that NERLYNX is expected to make up the vast majority of product revenue for the foreseeable future, while research-and-development costs rose in the first quarter on higher alisertib trial activity. Any slowdown in NERLYNX demand, weaker trial data, or a cost jump would press the stock quickly.
For now, PBYI is not trading like a company with a new catalyst. It is trading like a small oncology name waiting for proof that the raised outlook can hold.
